Please login to the form below

LABA

This page shows the latest LABA news and features for those working in and with pharma, biotech and healthcare.

Novartis reveals full phase 3 results for Enerzair Breezhaler

Earlier this week, the European Commission approved Enerzair Breezhaler as a maintenance treatment for asthma in adults not adequately controlled with a maintenance combination of a long-acting beta2-agonist (LABA) ... symptoms despite receiving a

Latest news

The end of pharma

Looking back from the future, companies that marketed, say, insulin or LAMA/LABA drugs will seems like strange historical artefacts from another age.
AZ builds case for its COPD triple as it chases GSK’s Trelegy

Breztri – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – is playing catch-up in the market with GlaxoSmithKline’s
AZ prepares to file COPD triple, taking on rival GSK

The KRONOS trial of PT010 – which combines long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid (ICS) budesonide – was presented at a medical congress ... triple –
AZ rival to GSK’s COPD drug Anoro fails head-to-head test

The results of the AERISTO trial are a blow to AZ’s ambitions for Bevespi (glycopyrronium/formoterol fumarate) – a long-acting muscarinic agonist (LAMA)/long-acting beta agonist (LABA) combination that ... The real battleground between the two
AZ’s COPD triple data sets up market clash with GSK

AZ has reported phase III data from the KRONOS trial of its PT010 triple - combining long-acting beta agonist (LABA) formoterol fumarate, long-acting muscarinic antagonist (LAMA) glycopyrronium and inhaled corticosteroid ... on LABA vilanterol,

More from news
Approximately 3 fully matching, plus 59 partially matching documents found.

Latest Intelligence

Could formulary intelligence be your brand differentiator?

Spiolto – a LAMA/LABA combination for COPD and heir to Boehringer’s blockbuster Spiriva.
GSK forges ahead with its dynamic COPD and asthma portfolio

For instance, in the UK, US, Canada and Spain, the first treatment was an ICS/LABA, such Seretide or Symbicort, while in Germany it was a bronchodilator.
Deal Watch table for June 2013

2, 150. Pearl Therapeutics / AstraZeneca. Acquisition. Inhaled small molecules including PT003 fixed dose combination (LABA/ LAMA for COPD (phase III).
Pharma deals during June 2013

2 agonist (LABA) and a long acting muscarinic antagonist (LAMA) is expected to become an important new class of treatment.

More from intelligence
Approximately 0 fully matching, plus 4 partially matching documents found.

COVID-19 Updates and Daily News

Featured jobs

PMHub

Add my company

Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

Switzerland: a life sciences hub: Switzerland has a rich diversity of pharma and biotech companies that sustain activity and help maintain its reputation as a highly innovative country...
Responding to dynamic shifts in value communications: OPEN Health’s Beth Lesher and Annemarie Clegg examine what the convergence of medical communications and market access means for pharmaceutical companies....
Doing what we can and having fun doing it: our fundraising month: Charities are facing a number of challenges just to stay afloat amidst the current COVID-19 pandemic. Fundraisers are being cancelled and public donations are not as abundant as they have...